{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:39:43Z","timestamp":1791250783861,"version":"4.1.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Osteosarcoma (OS) is the most common primary bone tumor in children and adolescents. Ninety percent of patients who present with metastatic and 30% to 40% of patients with nonmetastatic disease experience relapse, creating an urgent need for novel therapeutic strategies. The Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), are important for mitosis, motility, and cell survival. Upregulation of Met\/HGF signaling via receptor overexpression, amplification, or mutation drives the proliferation, invasiveness, and metastasis of a variety of cancer cells, including OS, prompting the development of Met\/HGF inhibitors. OS cells depend on Met overexpression because introduction of dominant-negative Met inhibits in vivo tumorigenicity. Despite the importance of Met\/HGF signaling in the development and maintenance of OS, the potential efficacy of pharmacologic Met inhibition in OS has been addressed only in in vitro studies. PF-2341066 is an orally bioavailable, selective ATP-competitive Met inhibitor that showed promising results recently in a phase I clinical trial in non\u2013small cell lung cancer (NSCLC) patients. We tested the ability of PF-2341066 to inhibit malignant properties of osteosarcoma cells in vitro and orthotopic xenograft growth in vivo. In vitro, PF-2341066 inhibited osteosarcoma behavior associated with primary tumor growth (eg, proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). In nude mice treated with PF-2341066 via oral gavage, the growth and associated osteolysis and extracortical bone matrix formation of osteosarcoma xenografts were inhibited by PF-2341066. PF-2341066 may represent an effective new systemic therapy for localized and potentially disseminated osteosarcoma. \u00a9 2011 American Society for Bone and Mineral Research.<\/jats:p>","DOI":"10.1002\/jbmr.336","type":"journal-article","created":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T21:45:13Z","timestamp":1296596713000},"page":"1283-1294","source":"Crossref","is-referenced-by-count":46,"title":["The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis\/matrix production in a xenograft model"],"prefix":"10.1093","volume":"26","author":[{"given":"Erik R","family":"Sampson","sequence":"first","affiliation":[{"name":"Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad A","family":"Martin","sequence":"additional","affiliation":[{"name":"Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee E","family":"Morris","sequence":"additional","affiliation":[{"name":"Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Xie","sequence":"additional","affiliation":[{"name":"Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward M","family":"Schwarz","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics, University of Rochester Medical Center, Rochester, NY, USA"},{"name":"Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regis J","family":"O'Keefe","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics, University of Rochester Medical Center, Rochester, NY, USA"},{"name":"Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy N","family":"Rosier","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics, University of Rochester Medical Center, Rochester, NY, USA"},{"name":"Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,2,1]]},"reference":[{"key":"2024020318040509400_bib1","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/jbmr.77","article-title":"Osteosarcoma","volume":"25","author":"Gorlick","year":"2009","journal-title":"J Bone Miner Res."},{"key":"2024020318040509400_bib2","doi-asserted-by":"crossref","first-page":"515","DOI":"10.5435\/00124635-200908000-00005","article-title":"Osteosarcoma","volume":"17","author":"Messerschmitt","year":"2009","journal-title":"J Am Acad Orthop Surg."},{"key":"2024020318040509400_bib3","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/path.2549","article-title":"Met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcoma","volume":"218","author":"De Maria","year":"2009","journal-title":"J Pathol."},{"key":"2024020318040509400_bib4","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/nrm1261","article-title":"Met, metastasis, motility and more","volume":"4","author":"Birchmeier","year":"2003","journal-title":"Nat Rev Mol Cell Biol."},{"key":"2024020318040509400_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2004.09.044","article-title":"c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention","volume":"225","author":"Christensen","year":"2005","journal-title":"Cancer Lett."},{"key":"2024020318040509400_bib6","first-page":"381","article-title":"Expression of the met-receptor and its ligand, HGF-SF during mouse embryogenesis","volume":"65","author":"Sonnenberg","year":"1993","journal-title":"Exs."},{"key":"2024020318040509400_bib7","doi-asserted-by":"crossref","first-page":"11445","DOI":"10.1073\/pnas.94.21.11445","article-title":"Activating mutations for the met tyrosine kinase receptor in human cancer","volume":"94","author":"Jeffers","year":"1997","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2024020318040509400_bib8","doi-asserted-by":"crossref","first-page":"10722","DOI":"10.1073\/pnas.191067898","article-title":"Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase","volume":"98","author":"Furge","year":"2001","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2024020318040509400_bib9","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1073\/pnas.94.2.701","article-title":"Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor\/scatter factor","volume":"94","author":"Takayama","year":"1997","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2024020318040509400_bib10","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1172\/JCI118744","article-title":"Transgenic expression of tpr-met oncogene leads to development of mammary hyperplasia and tumors","volume":"97","author":"Liang","year":"1996","journal-title":"J Clin Invest."},{"key":"2024020318040509400_bib11","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/BF00204976","article-title":"Hepatocyte growth factor\/scatter factor-Met signaling in tumorigenicity and invasion\/metastasis","volume":"74","author":"Jeffers","year":"1996","journal-title":"J Mol Med."},{"key":"2024020318040509400_bib12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2967\/jnumed.106.038836","article-title":"Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET","volume":"49","author":"Tseng","year":"2008","journal-title":"J Nucl Med."},{"key":"2024020318040509400_bib13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ccr.2004.05.032","article-title":"Targeting the tumor and its microenvironment by a dual-function decoy Met receptor","volume":"6","author":"Michieli","year":"2004","journal-title":"Cancer Cell."},{"key":"2024020318040509400_bib14","first-page":"7345","article-title":"A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo","volume":"63","author":"Christensen","year":"2003","journal-title":"Cancer Res."},{"key":"2024020318040509400_bib15","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.1158\/0008-5472.CAN-06-4443","article-title":"An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms","volume":"67","author":"Zou","year":"2007","journal-title":"Cancer Res."},{"key":"2024020318040509400_bib16","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1021\/bi900438w","article-title":"Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors","volume":"48","author":"Timofeevski","year":"2009","journal-title":"Biochemistry."},{"key":"2024020318040509400_bib17","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0092-8674(94)90318-2","article-title":"A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor\/scatter factor receptor family","volume":"77","author":"Ponzetto","year":"1994","journal-title":"Cell."},{"key":"2024020318040509400_bib18","first-page":"739","article-title":"The Met\/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit","volume":"10","author":"Ferracini","year":"1995","journal-title":"Oncogene."},{"key":"2024020318040509400_bib19","first-page":"5355","article-title":"Met expression and sarcoma tumorigenicity","volume":"53","author":"Rong","year":"1993","journal-title":"Cancer Res."},{"key":"2024020318040509400_bib20","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1158\/0008-5472.CAN-05-4422","article-title":"MET overexpression turns human primary osteoblasts into osteosarcomas","volume":"66","author":"Patane","year":"2006","journal-title":"Cancer Res."},{"key":"2024020318040509400_bib21","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1096\/fj.02-0576fje","article-title":"Role of the MET\/HGF receptor in proliferation and invasive behavior of osteosarcoma","volume":"17","author":"Coltella","year":"2003","journal-title":"Faseb J."},{"key":"2024020318040509400_bib22","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1007\/s11999-008-0338-9","article-title":"Specific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro","volume":"466","author":"Messerschmitt","year":"2008","journal-title":"Clin Orthop Relat Res."},{"key":"2024020318040509400_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1593\/neo.09948","article-title":"An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis","volume":"12","author":"Zillhardt","year":"2010","journal-title":"Neoplasia."},{"key":"2024020318040509400_bib24","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nrd2530","article-title":"Drug development of MET inhibitors: targeting oncogene addiction and expedience","volume":"7","author":"Comoglio","year":"2008","journal-title":"Nat Rev Drug Discov."},{"key":"2024020318040509400_bib25","author":"Kwak","year":"2009"},{"key":"2024020318040509400_bib26","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1073\/pnas.85.1.21","article-title":"Characterization of the TPR-MET oncogene p65 and the MET protooncogene p140 protein-tyrosine kinases","volume":"85","author":"Gonzatti-Haces","year":"1988","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2024020318040509400_bib27","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/318385a0","article-title":"The human met oncogene is related to the tyrosine kinase oncogenes","volume":"318","author":"Dean","year":"1985","journal-title":"Nature."},{"key":"2024020318040509400_bib28","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1158\/0008-5472.CAN-07-6186","article-title":"Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors","volume":"68","author":"McDermott","year":"2008","journal-title":"Cancer Res."},{"key":"2024020318040509400_bib29","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med."},{"key":"2024020318040509400_bib30","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1093\/jnci\/90.12.882","article-title":"Herceptin raises its sights beyond advanced breast cancer","volume":"90","author":"McNeil","year":"1998","journal-title":"J Natl Cancer Inst."},{"key":"2024020318040509400_bib31","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S1470-2045(07)70169-9","article-title":"Opportunities for improving the therapeutic ratio for patients with sarcoma","volume":"8","author":"Wunder","year":"2007","journal-title":"Lancet Oncol."},{"key":"2024020318040509400_bib32","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1101\/gad.1656808","article-title":"Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease","volume":"22","author":"Walkley","year":"2008","journal-title":"Genes Dev."},{"key":"2024020318040509400_bib33","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1073\/pnas.0805462105","article-title":"Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage","volume":"105","author":"Berman","year":"2008","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2024020318040509400_bib34","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1440-1827.1998.tb03834.x","article-title":"Coexpression of HGF and c-Met\/HGF receptor in human bone and soft tissue tumors","volume":"48","author":"Fukuda","year":"1998","journal-title":"Pathol Int."},{"key":"2024020318040509400_bib35","first-page":"5152","article-title":"Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor","volume":"12","author":"Rong","year":"1992","journal-title":"Mol Cell Biol."},{"key":"2024020318040509400_bib36","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1158\/0008-5472.CAN-07-3220","article-title":"Frzb, a secreted Wnt antagonist, decreases growth and invasiveness of fibrosarcoma cells associated with inhibition of Met signaling","volume":"68","author":"Guo","year":"2008","journal-title":"Cancer Res."},{"key":"2024020318040509400_bib37","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/08977190600759923","article-title":"The MET receptor tyrosine kinase contributes to invasive tumour growth in rhabdomyosarcomas","volume":"24","author":"Rees","year":"2006","journal-title":"Growth Factors."},{"key":"2024020318040509400_bib38","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10585-005-0365-9","article-title":"An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis","volume":"22","author":"Luu","year":"2005","journal-title":"Clin Exp Metastasis."},{"key":"2024020318040509400_bib39","author":"Niswander","year":"2010"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.336","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/26\/6\/1283\/56558973\/336_ftp.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/26\/6\/1283\/56558973\/336_ftp.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T15:00:50Z","timestamp":1710342050000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/26\/6\/1283-1294\/7598104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,1]]},"references-count":39,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2011,2,1]]},"published-print":{"date-parts":[[2011,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.336","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,6,1]]},"published":{"date-parts":[[2011,2,1]]}}}